Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy

Journal of Clinical Oncology

Volumn 28, Issue 9, 2010, Pages 1481-1488

  Ryan, Charles J ^a   Smith, Matthew R ^a   Fong, Lawrence ^a   Rosenberg, Jonathan E ^a   Kantoff, Philip ^a   Raynaud, Florence ^a   Martins, Vanessa ^a   Lee, Gloria ^a   Kheoh, Thian ^a   Kim, Jennifer ^a   Molina, Arturo ^a   Small, Eric J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; KETOCONAZOLE; MINERALOCORTICOID; PROSTATE SPECIFIC ANTIGEN; ABIRATERONE; ANDROSTANE DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; STEROID 17ALPHA MONOOXYGENASE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANDROGEN BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; CANCER RESISTANCE; CASTRATION; CLINICAL ARTICLE; CONSTIPATION; CORTICOSTEROID BLOOD LEVEL; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; DYSPEPSIA; EDEMA; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MALE; MUSCLE WEAKNESS; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; STEROIDOGENESIS; TREATMENT OUTCOME; VISCERAL METASTASIS; VOMITING; XEROSTOMIA; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; ORCHIECTOMY; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENOLS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT OUTCOME;

EID: 77951523950     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.1281     Document Type: Article

References (19)

1. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
2. Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
3. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004 (Pubitemid 39315318)
4. Slovin SF: Neuroendocrine differentiation in prostate cancer: A sheep in wolf's clothing? Nat Clin Pract Urol 3:138-144, 2006
5. Pienta KJ, Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665-1671, 2006
6. Holzbeierlein J, Lal P, LaTulippe E, et al: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217-227, 2004 (Pubitemid 38364606)
7. Debes JD, Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488-1490, 2004 (Pubitemid 39315314)
8. Scher HI, Sawyers CL: Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253-8261, 2005 (Pubitemid 46211563)
9. Linja MJ, Savinainen KJ, Saramäki OR, et al: Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555, 2001 (Pubitemid 32694958)
10. Stanbrough M, Bubley GJ, Ross K, et al: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825, 2006
11. Small EJ, Halabi S, Dawson NA, et al: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033, 2004 (Pubitemid 41095034)
12. Haidar S, Ehmer PB, Barassin S, et al: Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 84:555-562, 2003 (Pubitemid 36588809)
13. Attard G, Reid AH, Yap TA, et al: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571, 2008
14. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999 (Pubitemid 29517916)
15. US Food and Drug Administration, Center for Evaluation and Research: Guidance for industry: Food-effect bioavailability and fed bioequivalence studies. http://www.fda.gov/ohrms/dockets/ac/02/briefing/3860b1-01-GFI-Food- effect.pdf
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Luthy IA, Begin DJ, Labrie F: Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 31:845-852, 1988 (Pubitemid 19006901)
18. Small EJ, Ryan CJ: The case for secondary hormonal therapies in the chemotherapy age. J Urol 176:S66-S71, 2006 (Pubitemid 44648139)
19. Ryan CJ, Halabi S, Ou SS, et al: Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a Cancer and Leukemia Group B study. Clin Cancer Res 13:2030-2037, 2007 (Pubitemid 46649869)